HAVCR2 and neoplasm: It also reduced the expression of CD4+CD25+FoxP+T, PD-L1, PD-1, TIM-3 protein in tumor tissues and the expression of PD-L1 and PD-1 mRNA in tumor tissues, increasing the effect of atezolizumab on the proliferation of lung cancer cells [134, 135].